Der Report
Verifizierte Nachrichten zu Finanzierung, Hauptsitzen und Führungskräften der innovativsten Unternehmen der Welt
169 Berichte und es werden mehr
Vir Biotechnology Raises $250M in Series E
Vir Biotechnology, a Biotech company based in 499 Illinois Street, San Francisco, CA 94158, has raised $250M in Series E at a $3.3B valuation led by SoftBank Vision Fund, Arch Venture Partners, ARCH Venture Partners, Intermediate Capital Group.
Vir Biotechnology raises $250M Series E at $3.3B valuation
Vir Biotechnology raises $250M in Series E at $3.3B valuation. Infectious disease treatment development...
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sana Biotechnology Raises $700M in IPO
Sana Biotechnology, a Biotech company based in 188 East Blaine Street, Seattle, WA 98102, has raised $700M in IPO at a $4.2B valuation led by Flagship Pioneering, ARCH Venture Partners, F-Prime Capital, Baillie Gifford.
Arbor Biotechnologies Raises $215M in Series C
Arbor Biotechnologies, a Biotech company based in 830 Winter Street, Waltham, MA 02451, has raised $215M in Series C at a $800M valuation led by Lightspeed Venture Partners, Redmile Group, Agent Capital, Amplitude Ventures.
Arbor Biotechnologies raises $215M Series C at $800M valuation
Arbor Biotechnologies raises $215M in Series C at $800M valuation. Gene editing technologies...
Sana Biotechnology raises $700M IPO at $4.2B valuation
Sana Biotechnology raises $700M in IPO at $4.2B valuation. Cell and gene therapy platform...
Cogent Biosciences Raises $475.3 million in Public Offering
Cogent Biosciences, a Biotechnology company based in Waltham MA, has raised $475.3 million in Public Offering at a Undisclosed led by Public market investors.
SciNeuro Raises $53 million in Series B
SciNeuro, a Biotechnology company based in Shanghai China, has raised $53 million in Series B at a Undisclosed led by Chinese.
9 Berichte angezeigt • Seite 1 • Kategorie: all
Bleiben Sie dem Markt voraus
Erhalten Sie wöchentliche Insights direkt in Ihren Posteingang. Kein Spam, nur Intelligence.